Tracon Pharmaceuticals | DEF 14A: Definitive information statements

Tracon Pharmaceuticals | DEF 14A：股東委託書決議

Moomoo AI 已提取核心訊息

Tracon Pharmaceuticals, Inc. (Tracon) has announced a Special Meeting of Stockholders scheduled for October 11, 2024, to vote on the proposed liquidation and dissolution of the company. The Board of Directors has reviewed the company's financial position, including its lack of revenue sources and unsuccessful attempts to secure financing or strategic alternatives, and unanimously recommends that stockholders vote in favor of the dissolution. The dissolution plan involves liquidating the company's assets, satisfying its obligations, and potentially distributing any remaining assets to stockholders. The company's efforts to monetize its rights to data from clinical trials of TRC102 have not succeeded to date, and the Board currently believes that any alternatives to dissolution are likely limited. If the dissolution is approved, the company will cease business operations except for those necessary to wind up affairs, and it will no longer be publicly traded. The Board may also establish a liquidating trust to manage the distribution of assets. The company does not expect any amounts to be available for distribution to stockholders in connection with the dissolution.

Tracon Pharmaceuticals, Inc.（Tracon）宣佈將於2024年10月11日舉行特別股東大會，就公司提議的清算和解散進行投票。董事會已經審查了公司的財務狀況，包括缺乏收入來源以及未能成功融資或尋找戰略替代方案，一致建議股東投票贊成解散。解散計劃涉及清算公司資產，償還債務，並有可能將剩餘資產分配給股東。公司嘗試將TRC102臨床試驗數據的權益變現至今未成功，董事會目前認爲除解散外的任何替代方案可能有限。如果解散獲得批准，公司將停止除了進行結賬事務以外的營業活動，並且將不再公開交易。董事會還可能設立一個清算信託來管理資產分配。公司預計在清算過程中不會有任何金額可供分配給股東。

有用

沒用

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息

Tracon Pharmaceuticals | DEF 14A: Definitive information statements

Tracon Pharmaceuticals | DEF 14A: Definitive information statements

Moomoo AI 已提取核心訊息

風險及免責聲明

聲明